Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: Results of a randomized phase 2 trial

Dogliotti L., Carteni G., Siena S., Bertetto O., Martoni A., Bono A., ...More

EUROPEAN UROLOGY, vol.52, no.1, pp.134-141, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 52 Issue: 1
  • Publication Date: 2007
  • Doi Number: 10.1016/j.eururo.2006.12.029
  • Journal Name: EUROPEAN UROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.134-141
  • Istanbul University Affiliated: No


objectives: This phase 2 randomized study compared the toxicity and assessed the efficacy of gemcitabine-cisplatin (GP) and gemcitabine-carboplatin (GC) in patients with advanced transitional. cell carcinoma of the urothelium (TCC), with the main objective to demonstrate a reduction in toxicity of at least 25% in the GC arm.